<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676806</url>
  </required_header>
  <id_info>
    <org_study_id>UCBT001</org_study_id>
    <nct_id>NCT00676806</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Umbilical Cord Blood Transplantation</brief_title>
  <official_title>A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be
      substituted for adult bone marrow cells in the standard stem cell transplant regimens used at
      this hospital for subjects who do not have stem cell donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic stem cell transplantation (SCT) following myeloablative and non-myeloablative
      conditioning therapy has proven curative treatment for a number of inherited and acquired
      hematologic disorders. The success of allogeneic transplantation is largely determined by
      compatibility between donor and recipient, which predicts the risk of fatal graft-versus-host
      disease (GVHD). Unfortunately, less than one third of patients needing an allogeneic
      transplant have an available compatible donor in their family. Registries have been
      established to match patients with compatible volunteer (unrelated) donors, but many
      patients, and in particular minority patients, still lack stem cell donors.

      Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells, which is readily
      available from the placenta following childbirth. Blood banks have been established in the
      United States and abroad to collect, process and store UCB for use in allogeneic
      transplantation. To date, more than 2000 UCB transplants have been performed in adults and
      children around the world.

      Rationale for use of Umbilical Cord Blood in Transplantation

      UCB has a number of proven and theoretical advantages as an alternative source of
      hematopoietic stem cells for transplantation:

        1. Placental or umbilical cord blood is an abundantly available source of stem cells, which
           is currently discarded and can be harvested at no risk to the mother or infant.

        2. Important infectious agents, particularly CMV, are much less common in the newborn than
           adults, and are less likely to contaminate UCB collections.

        3. UCB collections, typed, cryopreserved and banked, are available on demand, eliminating
           delays and uncertainties that now complicate marrow collection from unrelated donors. At
           present, UCB can be delivered for infusion within days of the initiation of a search.
           This compares with a median of 3 months from search to delivery of stem cells through
           the registries of volunteer adult donors.

        4. The intensity of graft-versus-host reactivity of fetal lymphocytes appears to be less
           than that of adult cells and consequently fetal lymphocytes are more tolerant of HLA
           incompatibility. Published studies have shown that transplantation of UCB matched at
           4-5/6 antigens results in a comparable incidence of GVHD to transplantation of unrelated
           stem cells fully matched at 6/6 antigens.

        5. Frozen UCB can be easily shipped, stored at the treating institution, and thawed for use
           when needed, compared to freshly donated stem cells which have a limited shelf-life of
           one day or less, necessitating coordination between harvesting surgeons, transportation,
           and transplantation teams.

      This research study has been designed for people who have been diagnosed with a blood tumor,
      which has not responded to treatment or has recurred, a bone marrow failure state such as
      aplastic anemia, or one of certain inherited metabolic disorders; and whose doctor feels the
      best treatment is an allogeneic stem cell transplant (alloSCT) but a related or unrelated
      adult donor is not available. Instead, a single unit of umbilical cord blood (UCB) will be
      used as the source of the subject's immune system. This study is designed to determine
      whether a single unit of UCB can be substituted for adult bone marrow cells in the standard
      stem cell transplant regimens used at this hospital for subjects who do not have stem cell
      donors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Neutrophil Engraftment</measure>
    <time_frame>+45 and 90 days</time_frame>
    <description>Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Platelet Engraftment</measure>
    <time_frame>+45, 90, and 180 days</time_frame>
    <description>Proportion of patients engrafting by days +45, +90, and +180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute GVHD</measure>
    <time_frame>Day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Complications in UCB Recipients.</measure>
    <time_frame>Day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>After Day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation</measure>
    <time_frame>+180 days</time_frame>
    <description>Composite endpoint of GVH or infection. Too few events to compare between arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Myeloablative conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord blood for hematopoietic rescue following myeloablative conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced intensity conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Blood After Myeloablative Conditioning</intervention_name>
    <description>cyclophosphamide (60mg/m2 days -6 &amp; -5), fludarabine (25 mg/m2 days -7, -6, &amp; -5) and total body irradiation (days -3, -2, &amp; -1, total 1200 cGy) followed by cord blood infusion on day 0.</description>
    <arm_group_label>Myeloablative conditioning</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>TBI</other_name>
    <other_name>Fludara</other_name>
    <other_name>Busulfex</other_name>
    <other_name>UCBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Blood After Reduced-Intensity Conditioning</intervention_name>
    <description>Extracorporeal Photopheresis (days -8 &amp; -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 &amp; -4), total body irradiation (days -3 &amp; -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.</description>
    <arm_group_label>Reduced intensity conditioning</arm_group_label>
    <other_name>Psoralen</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Nypent</other_name>
    <other_name>TBI</other_name>
    <other_name>UCBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting eligibility criteria for unrelated allogeneic stem cell transplantation
        may be considered for participation on this clinical trial if and only if they meet each of
        the following criteria:

          -  Patients must have one of the following diagnoses

          -  Relapsed or refractory hematologic malignancy, or

          -  High risk hematologic malignancy in first remission, or

          -  Refractory acquired marrow failure state, or

          -  Inherited disorder of metabolism or marrow failure state without alternative curative
             therapy.

          -  Patients must not have a 6/6 or 5/6 HLA-matched related donor.

          -  Patients must not have a HLA-A, -B and -DRB1 high resolution matched unrelated donor
             following registry search, or cannot (in the opinion of the treating physician) wait
             the median 3 months to receive a MUD unit.

          -  Patients must demonstrate an ability to understand and willingness to sign the
             informed consent document

        Patients considered for myeloablative conditioning must satisfy the following additional
        criteria:

          -  Patients must be up to age 55 (inclusive)

          -  Patients must have serum direct bilirubin ≤ 2.0 mg/dl and transaminases ≤ 2x
             institution upper limit of normal

          -  Patients must have serum creatinine ≤ 2 mg/dl with creatinine clearance ≥ 60 ml/min
             (either calculated or measured).

          -  Patients must have MUGA scan or echocardiogram normal for the institution, but not
             less than 45% left ventricular ejection fraction and no clinical evidence of cardiac
             dysfunction.

          -  Patients must have an ECOG performance status of 0 or 1 (see Appendix C).

          -  Patients must have adequate pulmonary function when corrected for hemoglobin and
             alveolar volume as evidenced by a diffusion capacity and FEV1 &gt; 50% of predicted.

        Patients considered for reduced-intensity conditioning must satisfy the following
        additional criteria:

          -  Patients must not be candidates for myeloablative conditioning due to any one of the
             following: Prior myeloablative stem cell transplantation, Age &gt; 50, Co morbid illness

          -  In opinion of treating physician, unable to comply with or withstand rigors of
             myeloablative conditioning

          -  Patients with leukemia must have circulating and bone marrow blast counts &lt; 5%, all
             other patients must have chemotherapy responsive disease

          -  Patients must be between the ages of 18 and 70 (inclusive)

          -  Patients must have serum direct bilirubin ≤ 2.0 mg/dL and transaminases ≤ 3x
             institution upper limit of normal

          -  Patients must have creatinine clearance ≥ 30 ml/min (either calculated or measured).

          -  Patients must have MUGA scan or echocardiogram documenting left ventricular ejection
             fraction of no less than 35% and no clinical evidence of cardiac dysfunction.

        Patients must have an ECOG performance status of 0 or 1 (see Appendix C).

        Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar
        volume as evidenced by a diffusion capacity and FEV1 ≥ 40% of predicted.

        Exclusion Criteria:

        Patients are ineligible for participation on this trial if they meet any of the following
        criteria:

          -  Patients with a history of myocardial infarction within the preceding 6 months,
             significant arrhythmia within the preceding 3 months, uncontrolled hypertension or
             congestive heart failure are ineligible.

          -  Patients with unstable angina are not eligible.

          -  Pregnant or lactating women are ineligible.

          -  Male and female patients who do not agree to practice approved methods of birth
             control for the duration of the study are ineligible.

          -  Patients with uncontrolled infection are ineligible.

          -  Patients who are HIV positive or have evidence of chronic viral hepatitis are
             ineligible.

          -  Patients unable to comply with requirements for compliance with therapeutic plan
             and/or scheduled evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <results_first_submitted>May 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Umbilical cord blood transplantation</keyword>
  <keyword>full ablation conditioning</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject signed consent but did not receive a transplant, so was dropped from the study and was not assigned to either arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Myeloablative Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning
Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 &amp; -5), fludarabine (25 mg/m2 days -7, -6, &amp; -5) and total body irradiation (days -3, -2, &amp; -1, total 1200 cGy) followed by cord blood infusion on day 0.</description>
        </group>
        <group group_id="P2">
          <title>Reduced Intensity Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 &amp; -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 &amp; -4), total body irradiation (days -3 &amp; -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Myeloablative Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning
Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 &amp; -5), fludarabine (25 mg/m2 days -7, -6, &amp; -5) and total body irradiation (days -3, -2, &amp; -1, total 1200 cGy) followed by cord blood infusion on day 0.</description>
        </group>
        <group group_id="B2">
          <title>Reduced Intensity Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 &amp; -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 &amp; -4), total body irradiation (days -3 &amp; -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="8.1"/>
                    <measurement group_id="B2" value="62.6" spread="2.3"/>
                    <measurement group_id="B3" value="52.8" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neutrophil Engraftment</title>
        <description>Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning</description>
        <time_frame>+45 and 90 days</time_frame>
        <population>Only 2 subjects were evaluable from each group at the +45 day mark. The same number were evaluable at the +90 day mark.</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.
2/2 evaluable subjects engrafted at +45 and +90 days.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
1/2 evaluable subjects engrafted at +45 and +90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil Engraftment</title>
          <description>Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning</description>
          <population>Only 2 subjects were evaluable from each group at the +45 day mark. The same number were evaluable at the +90 day mark.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Platelet Engraftment</title>
        <description>Proportion of patients engrafting by days +45, +90, and +180.</description>
        <time_frame>+45, 90, and 180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Platelet Engraftment</title>
          <description>Proportion of patients engrafting by days +45, +90, and +180.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelet Engraftment +45 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment +90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment +180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute GVHD</title>
        <time_frame>Day +100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute GVHD</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infectious Complications in UCB Recipients.</title>
        <time_frame>Day +100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Infectious Complications in UCB Recipients.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <time_frame>After Day +100</time_frame>
        <population>No subject receiving reduced intensity conditioning was evaluable for the event of chronic GVHD (0/3 subjects survived to day +100)</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <population>No subject receiving reduced intensity conditioning was evaluable for the event of chronic GVHD (0/3 subjects survived to day +100)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation</title>
        <description>Composite endpoint of GVH or infection. Too few events to compare between arms.</description>
        <time_frame>+180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.
2/2 evaluable subjects engrafted at +45 and +90 days. 3 evaluable subjects for toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning</title>
            <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
1/2 evaluable subjects engrafted at +45 and +90 days. 3 evaluable subjects for toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation</title>
          <description>Composite endpoint of GVH or infection. Too few events to compare between arms.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Myeloablative Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning
Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 &amp; -5), fludarabine (25 mg/m2 days -7, -6, &amp; -5) and total body irradiation (days -3, -2, &amp; -1, total 1200 cGy) followed by cord blood infusion on day 0.</description>
        </group>
        <group group_id="E2">
          <title>Reduced Intensity Conditioning</title>
          <description>Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 &amp; -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 &amp; -4), total body irradiation (days -3 &amp; -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal GVHD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Likely d/t severe medical illness, renal failure, and medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Nodules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andreas Klein, MD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-8884</phone>
      <email>aklein2@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

